Bristol Confident To Move Deucravacitinib Into Phase III Lupus Trial
Executive Summary
A Phase II study testing the TYK2 inhibitor in systemic lupus erythematosus met the primary endpoint. CMO Samit Hirawat talked to Scrip about the data and future development.
You may also be interested in...
Nimbus Nips At BMS’s Heels With Psoriasis Results For TYK2 Inhibitor
Without disclosing data, Nimbus announced positive Phase IIb results for NDI-034858 in psoriasis. The company plans to initiate a Phase III trial next year.
BMS Aims To Unseat Otezla In Psoriasis With US FDA-Approved Sotyktu
Chief commercialization officer Chris Boerner said BMS plans to replace Otezla as the oral standard of care for moderate-to-severe psoriasis with Sotyktu (deucravacitinib); its list price is about 40% higher than Amgen’s product.
Roivant Cuts Multiple R&D Programs As It Takes On Pfizer’s TYK2/JAK1 Inhibitor
Roivant and Pfizer launched Priovant to develop the oral drug brepocitinib for dermatomyositis, lupus and other autoimmune diseases, but Roivant also cut programs to extend its cash runway.